Nanoparticle aided glycovariant biomarkers for monitoring lung cancer
Sahlman, Saara (2023-05-15)
Nanoparticle aided glycovariant biomarkers for monitoring lung cancer
(15.05.2023)
Julkaisu on tekijänoikeussäännösten alainen. Teosta voi lukea ja tulostaa henkilökohtaista käyttöä varten. Käyttö kaupallisiin tarkoituksiin on kielletty.
suljettu
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2023061555229
https://urn.fi/URN:NBN:fi-fe2023061555229
Tiivistelmä
Lung cancer is no. 1 in cancer related cause of deaths worldwide in both sexes, according
to WHO. Lung cancers high mortality rate is mainly caused by late diagnosis. Most
patients have stage III or IV disease at the time of diagnosis. Common treatments for
lung cancer are surgery, radiofrequency ablation, radiation therapy, chemotherapy,
targeted drug therapy, immunotherapy, and palliative procedures. The ability to
monitor cancer response to various treatments would help in selecting the most
effective therapy forms.
Glycoproteins are cells main components. Glycosylation enables high variation of
different protein functions. Numerous glycoproteins are used as cancer biomarker with
different cancers. However, because they are also found in other benign disease
conditions along with healthy individuals and hence lack specificity. Cancer cells differ
highly from normal cells, they also have their own altered glycosylation patterns. These
altered glycoproteins are specific to the cancer and are highly promising target to search
for new biomarkers.
Glycan binding proteins include for e.g., lectins and antibodies that bind specifically to
certain glycan structures. They are found in all living organisms and hence have highly
variable targets. In this study, we use lectins to find different glycoforms of CA19-9,
CA15-3, and CA125 glycoproteins from lung cancer patients EDTA plasma samples. Due
to the low dissociation constant of lectins, we coat them on highly fluorescent europium
chelate dyed nanoparticles to increase the binding affinity. Seven different capture
F(ab)2 were used to track different glycoproteins: C192, C241, C242, Ma552, Ma695,
Ov185 and Ov197 and six different lectins to detect different glycoforms: MGL, MBL, TJA
II, AOL, WGA, and UEA I.
We found that three CA19-9 glycovariants (C192-WGA, C241-TJA II and C241- AOL) and
one CA15-3 glycovariant (Ma552-TJA II) followed most effectively the progressive and
regressive lung cancer disease in patients over time. Standards were established and the
glycovariant assays showed good linearity. Results were compared to CA19-9 and CA15-
3 commercial kits from Fujirebio, and it was observed that it is beneficial to detect
specific glycovariant instead of the glycoprotein itself. Overall, these four glycovariant
based assays show potential for use in monitoring of lung cancer.
to WHO. Lung cancers high mortality rate is mainly caused by late diagnosis. Most
patients have stage III or IV disease at the time of diagnosis. Common treatments for
lung cancer are surgery, radiofrequency ablation, radiation therapy, chemotherapy,
targeted drug therapy, immunotherapy, and palliative procedures. The ability to
monitor cancer response to various treatments would help in selecting the most
effective therapy forms.
Glycoproteins are cells main components. Glycosylation enables high variation of
different protein functions. Numerous glycoproteins are used as cancer biomarker with
different cancers. However, because they are also found in other benign disease
conditions along with healthy individuals and hence lack specificity. Cancer cells differ
highly from normal cells, they also have their own altered glycosylation patterns. These
altered glycoproteins are specific to the cancer and are highly promising target to search
for new biomarkers.
Glycan binding proteins include for e.g., lectins and antibodies that bind specifically to
certain glycan structures. They are found in all living organisms and hence have highly
variable targets. In this study, we use lectins to find different glycoforms of CA19-9,
CA15-3, and CA125 glycoproteins from lung cancer patients EDTA plasma samples. Due
to the low dissociation constant of lectins, we coat them on highly fluorescent europium
chelate dyed nanoparticles to increase the binding affinity. Seven different capture
F(ab)2 were used to track different glycoproteins: C192, C241, C242, Ma552, Ma695,
Ov185 and Ov197 and six different lectins to detect different glycoforms: MGL, MBL, TJA
II, AOL, WGA, and UEA I.
We found that three CA19-9 glycovariants (C192-WGA, C241-TJA II and C241- AOL) and
one CA15-3 glycovariant (Ma552-TJA II) followed most effectively the progressive and
regressive lung cancer disease in patients over time. Standards were established and the
glycovariant assays showed good linearity. Results were compared to CA19-9 and CA15-
3 commercial kits from Fujirebio, and it was observed that it is beneficial to detect
specific glycovariant instead of the glycoprotein itself. Overall, these four glycovariant
based assays show potential for use in monitoring of lung cancer.